BeOne Medicines: Guidance Weighs But Multiple Catalysts In 2026
Source: SeekingAlpha
2026-02-28 09:15:00 ET
On Thursday morning , BeOne Medicines ( ONC ) reported earnings and issued guidance for 2026. While Q4 earnings and revenue beat the Street's expectations, the outlook missed by a small margin, with the midpoint 2.3% below what analysts had projected for 2026 sales. The stock sold off and is now down over 10% since last week. Despite the soft guidance, this abrupt dip presents long-term investors with attractive prices to purchase shares....
Read the full article on Seeking Alpha
For further details see:
BeOne Medicines: Guidance Weighs But Multiple Catalysts In 2026
BeiGene Ltd.
NASDAQ: ONC
ONC Trading
2.02% G/L:
$299.05 Last:
159,174 Volume:
$292.50 Open:
ONC Latest News
February 26, 2026 06:00:00 am
BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership
February 20, 2026 04:03:28 pm
HHLR Advisors Fully Exits Baidu as AI Push Tests Its Advertising-Funded Model
ONC Stock Data
$39,109,836,794
83,911,918
0.1%
106
N/A
Biotechnology & Life Sciences
Healthcare
CH
Basel
